MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment

nDimensionsIP
Mar 17, 2016
1 min read

MediciNova has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (Ibudilast) for the treatment of amyotrophic lateral sclerosis (ALS).[More]

Recent Posts

See All

General Motors gets Indian patent related to powertrain technology

General Motors has secured an Indian patent on a hybrid powertrain control system for vehicles. The patent rights are currently assigned...

Trademarks Office: Abandonment orders kept in abeyance

Taking into consideration the Delhi High court’s order staying the abandonment orders passed by the Trademarks Office, the Registrar of...

Delhi High Court: No “irreconcilable conflict” between the Competition Act and the Patents Act

The order of the Delhi High Court allows the Competition Commission of India (CCI) to attend to complaints on abuse of dominance of...

nDimensions IP

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment

Recent Posts

Comments

Working Hours

Contact Us